Company Overview and News

to your dashboard

Headline News

An Integrated BioSci Research On Gilead Sciences: Promising Dividends And Favorable Valuations

8h seekingalpha
CAR-T to power future dividend growth while the hepatitis franchise expansion into China will boost further prospects. (24-0)

An Integrated Research On Global Blood Therapeutics: Is Voxelotor The Answer For Sickle Cell Disease?

2017-11-19 seekingalpha
The independent data and safety monitoring board completed the safety review of the phase 3 HOPE trial. (23-0)

Ligand Pharmaceuticals' (LGND) Presents at Analyst Day (Transcript)

2017-11-15 seekingalpha
Welcome. Thank you, everyone, for joining us. Ligand's end-of-the-year Analyst Day 2018 and beyond. We appreciate the turnout. We got a nice group on the audience today. The attendees on the webcast that continue to add and we really do appreciate your attention here at the end of day and close to the end of the year. My name is John Higgins, I'm the CEO of Ligand. I'm joined by several of our colleagues. (115-0)

Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity"), following which we have published a free report that can be viewed by signing up at The Company announced on November 10, 2017, Phase-1 clinical and translational data for IPI-549, its oral immuno-oncology development candidate. (84-0)

Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised

2017-11-10 zacks
Ligand Pharmaceuticals Inc. (LGND - Free Report) reported third-quarter 2017 adjusted earnings of 69 cents per share, significantly up 56.8% from the year-ago figure of 44 cents. The bottom line also beat the Zacks Consensus Estimate of 60 cents. (76-0)

Stonegate Capital Partners Updates Coverage on Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI)

2017-11-08 accesswire
Spectrum Pharmaceuticals, Inc. is focused on the acquisition, development and commercialization of proprietary drugs, primarily addressing the oncology/hematology markets. Spectrum's business strategy involves in-licensing or acquiring diversified drugs as well as creating an expanding pipeline of prospective candidates in late-stage Phase 2 and Phase 3 clinical trials. Over the years, the Company has developed comprehensive in-house clinical development/regulatory capabilities, along with an extensive commercial network, including a direct sales force in the U.

Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

2017-11-04 zacks
Spectrum Pharmaceuticals, Inc. SPPI incurred a loss of 22 cents per share in the third quarter of 2017, slightly narrower than the Zacks Consensus Estimate of a loss of 23 cents and in line with the year-ago loss. However, adjusted loss came in at 11 cents, wider-than the year ago loss of 7 cents. (72-0)

Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q3 2017 Results - Earnings Call Transcript

2017-11-03 seekingalpha
Good day, ladies and gentlemen, and thank you for standing by. Welcome to Spectrum Pharmaceuticals Q3 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference will be recorded. (0-1)

What to Expect from Keryx (KERX) This Earnings Season?

2017-10-31 zacks
Keryx Biopharmaceuticals, Inc. (KERX - Free Report) is expected to report third-quarter 2017 results on Nov. 6 after the market closes. (115-0)

What's in Store for Intrexon (XON) This Earnings Season?

2017-10-31 zacks
Intrexon Corporation (XON - Free Report) is expected to report third-quarter 2017 results on Nov 6 after the market closes. (86-0)

Can Chesapeake (CHK) Keep Its Earnings Streak Alive in Q3?

2017-10-31 zacks
Chesapeake Energy Corporation (CHK - Free Report) is slated to report third-quarter 2017 results on Nov 2, before the opening bell. (118-0)

Oil & Gas Stock Roundup: Exxon, Chevron, TOTAL Report Strong Q3

2017-10-31 zacks
It was a week where the price of oil spiked to its highest mark in nearly eight months. However, natural gas futures fell sharply. (32-0)

Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

2017-10-31 zacks
Spectrum Pharmaceuticals, Inc. (SPPI - Free Report) is scheduled to report third-quarter 2017 results on Nov. 2 after the market closes. (39-0)

Insight From The Stellar Scientist Trader - An Integrated BioSci Investing Report

2017-10-25 seekingalpha
In the previous week, Dr. Tran BioSci of Integrated BioSci Investing had the honor to sit down with the expert, Decision Analytics in an interview. Our readers greatly benefited from his wisdom. His recommendation on Spectrum Pharmaceuticals (NASDAQ:SPPI) proved correct. The stock increased 36% the following day (and reached its 52-weeks high) after the accurate forecasting of the phase 2 trial (which studied poziotinib as a treatment for non small cell lung cancer with exon 20 mutation). (372-5)

CUSIP: 84763A108